ABSTRACT
Prostaglandin analogues, latanoprost and travoprost, and one of the prostamides, bimatoprost, are widely used in glaucoma practice with their efficacious intraocular pressure-lowering effect. Treatment-related trichomegaly, increase in periocular pigmentation and adnexal hair growth are well-known periocular changes. But recently, a new and infrequent side effect called prostaglandin-associated periorbitopathy characterized by deepening of the upper lid sulcus, ptosis, enophthalmus, regression in dermatochalasis and lower lid lateral orbital fat pad prolapsus has been determined. In this case report, we wanted to present this rare side effect in three glaucoma patients who received bimatoprost and travoprost and to remind related fundamental physiopathology.
Keywords:
Prostaglandin analogues, bimatoprost, periorbitopathy
References
1
Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging. 2002;19:231-48.
2
Hodge WG, Lachaine J, Steffensen I et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol. 2008;92:7-12.
3
Vogel R, Strahlman E, Rittenhouse KD. Adverse events associated with commonly used glaucoma drugs. Int Ophthalmol Clin. 1999;39:107-24.
4
Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol. 2002;47:203-18.
5
Casson RJ, Selva D. Lash ptosis caused by latanoprost. Am J Ophthalmol. 2005;139:932-3.
6
Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81:574-7.
7
Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg. 2008;24:302-7.
8
Tappeiner C, Perren B, Iliev ME, Frueh BH, Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost--can bimatoprost cause enophthalmos? Klin Monbl Augenheilkd. 2008;225:443-5.
9
Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. Ocul Pharmacol Ther. 2009;25:471-2.
10
Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009;53:176-9.
11
Aydin S, Işikligil I, Tekşen YA, Kir E. Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature. Cutan Ocul Toxicol. 2010;29:212-6.
12
Pasquale LR. Pristaglandin-associated periorbitopathy. Glaucoma Today (Therapeutics Update):Early Summer 2011.
13
Stjernschantz JW, Albert DM, Hu DN, Drago F, Wistrand PJ. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 2002;47:162-75.
14
Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47:185-202.
15
Putterman AM. A clamp for strengthening Müller's muscle in the treatment of ptosis. Modification, theory, and clamp for the Fasanella-Servat ptosis operation. Arch Ophthalmol. 1972;87:665-7.
16
Helliwell RJ, Adams LF, Mitchell MD. Prostaglandin synthases:recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids. 2004;70:101-13.
17
Fujimori K, Aritake K, Urade Y. A novel pathway to enhance adipocyte differentiation of 3T3-L1 cells by up-regulation of lipocalin-type prostaglandin D synthase mediated by liver X receptor-activated sterol regulatory element-binding protein-1c. J Biol Chem. 2007;282:18458-66.
18
Reginato MJ, Krakow SL, Bailey ST, Lazar MA. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem. 1998;273:1855-8.
19
Serro G, Lepak NM. PG F2a (FP) receptor agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem Biophys Res Commun. 1997;233:200-2.
20
Ueno T, Fujimori K. Novel suppression mechanism operating in early phase of adipogenesis by positive feedback loop for enhancement of cyclooxygenase-2 expression through prostaglandin F2α receptor mediated activation of MEK/ERK-CREB cascade. FEBS J. 2011;278:2901-12.
21
Davies SS, Ju WK, Neufeld AH, Abran D, Chemtob S, Roberts LJ 2nd. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther. 2003;19:45-54.
22
Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011;55:22-7.
